-
Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22 (envafolimab) in combination with chidamide as a functional cure for human immunodeficiency virus (HIV) infection has completed the enrollment of 15 HIV-infected patients. The study achieved this milestone in just two months since the first…
-
CDE Issues Guidelines for Anti-Tumor ADC Clinical Development
•
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and Development of Anti-Tumor Antibody Drug Conjugates” and is seeking public feedback for one month. The document aims to provide a framework for the rational design of clinical trials involving antibody drug conjugates (ADCs) for anti-tumor…
-
Eli Lilly Announces Global C-Suite Changes, New Leadership in China
•
US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio Gay-Ger, the current president and general manager of Eli Lilly China, will transition to the role of chief marketing officer and vice president of global marketing for Eli Lilly’s diabetes business. In his new role,…
-
China’s Policy Shifts Medical Device Procurement Toward Domestic Products
•
Local government policies in China have begun to direct public hospitals to prioritize the procurement of certain medical devices and technologies from domestic producers, where available. According to Nikkei.com, notices to this effect were issued in April in Hubei, Anhui, Shanxi, and Ningxia. This move reportedly follows a national-level internal…
-
Antengene Expands to Australia with New Melbourne Office
•
China-based biotech firm Antengene (HKG: 6996) announced the opening of its new office in Melbourne, Australia. This strategic move is aimed at supporting the company’s expansion in the Asia Pacific region, with the office covering functions including commercial operations, finance, medical affairs, and clinical and business development. Clinical Trials and…
-
Great Bay Bio Completes USD 15M Pre-Series B Financing to Advance AI Bioprocessing Platforms
•
Great Bay Bio (GBB), a Hong Kong-based biotechnology firm, announced the completion of a USD 15 million pre-Series B financing round. The funding round was led by Tiger Med’s Tiger Jade Capital, with participation from an unnamed “top life science MNC,” AEF Greater Bay Area Fund (managed by Gobi Partners…
-
Zhonghong Pulin Partners with Shanghai Pharma for Logistics and Distribution
•
China-based Zhonghong Pulin Medical Product Co., Ltd (SHE: 300981) has entered into a partnership with compatriot firm Shanghai Pharmaceutical Co., Ltd (SHA: 601607). The five-year agreement is designed to leverage and integrate the respective advantageous resources of both companies to achieve mutually beneficial outcomes. Financial details of the partnership were…
-
Suzhou Jade Biomedical Secures USD 10 Million Series B Financing
•
China-based Suzhou Jade Biomedical Co., Ltd reportedly raised USD 10 million in a Series B financing round led by VMS Group, with participation from Panacea Venture. The proceeds will be used for the purchase of instruments, reagents, and consumables for the company’s biological GMP testing business. Additionally, the funds will…
